No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BDX240719C240000
- 0.69
- -1.13-62.09%
15min DelayClose Jul 1 16:00 ET
1.03High0.69Low
1.03Open1.82Pre Close3 Volume2.27K Open Interest240.00Strike Price247.00Turnover18.01%IV4.98%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry0.69Extrinsic Value100Contract SizeAmericanOptions Type0.1423Delta0.0248Gamma352.72Leverage Ratio-0.0620Theta0.0155Rho50.19Eff Leverage0.1134Vega
Intraday
- 5D
- Daily
News
Evercore Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Cuts Target Price to $285
Evercore analyst Vijay Kumar maintains $Becton Dickinson & Co(BDX.US)$ with a buy rating, and adjusts the target price from $290 to $285.According to TipRanks data, the analyst has a success rate of 4
Evercore ISI Adjusts Price Target on Becton, Dickinson to $285 From $290, Maintains Outperform Rating
Becton, Dickinson (BDX) has an average outperform rating and a price target range of $240 to $325, according to analysts polled by Capital IQ. Price: 229.86, Change: +0.59, Percent Change: +0.26
BD's (BDX) New Research Tool to Aid Single-Cell Analysis
With Becton, Dickinson and Company (NYSE:BDX) It Looks Like You'll Get What You Pay For
Becton, Dickinson and Company's (NYSE:BDX) price-to-earnings (or "P/E") ratio of 49.1x might make it look like a strong sell right now compared to the market in the United States, where around half of
BD Has Commercially Launched New Single-cell Research Tool To Help Scientists Better Understand How Molecular Machinery Within A Cell Functions And It Regulates Changes That Can Lead To Cancer And Other Diseases
BD Has Commercially Launched New Single-cell Research Tool To Help Scientists Better Understand How Molecular Machinery Within A Cell Functions And It Regulates Changes That Can Lead To Cancer And Oth
New BD Research Tool Helps Scientists Study Cells That Are Often Key Culprits in the Development of Cancer and Infectious Diseases
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial launch of a new single-cell...
Comments
$Becton Dickinson & Co(BDX.US$ GAME OVER stock.
Despite a dip in earnings, Becton Dickinson's high P/E ratio persists due to anticipated robust future growth, outpacing the broader market. Investors' confidence in the company's future earnings is high, indicating the share price is unlikely to drop significantly soon.
$Becton Dickinson & Co(BDX.US$ BD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device
2
Dr. Silverman's extensive experience and zeal for innovation, evidence generation, clinical development, medical safety, and compliance is predicted to boost BD's innovation pipeline and foster improved, personalized care.
Market sentiment towards Becton, Dickinson and Company shows no major shift in the past year. However, the rise in total shareholder return hints at a growing positivity.
Read more